X4 Pharmaceuticals Inc.

News & Events

Press Releases

In The Media

1. X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates

   GlobeNewswire MAY 1, 2025 6:01 AM EDT
   4WARD Phase 3 chronic neutropenia trial in full swing; full enrollment on track for 3Q or 4...
   READ ARTICLE

2. X4 Pharmaceuticals to Report First-Quarter 2025 Financial Results and Host Conference Call and Webcast on May 1, 2025

   GlobeNewswire APR 24, 2025 8:03 AM EDT
   BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a compa...
   READ ARTICLE

3. X4 Pharmaceuticals Announces Reverse Stock Split

   GlobeNewswire APR 24, 2025 8:00 AM EDT
   BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company d...
   READ ARTICLE

4. X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire APR 23, 2025 4:05 PM EDT
   BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company d...
   READ ARTICLE

5. X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

   GlobeNewswire MAR 25, 2025 6:01 AM EDT
   Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; ful...
   READ ARTICLE

6. X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2024 Financial Results and Host a Conference Call and Webcast on March 25, 2025

   GlobeNewswire MAR 11, 2025 8:00 AM EDT
   BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company d...
   READ ARTICLE

7. X4 Pharmaceuticals and taiba rare Announce Exclusive Agreement for the Distribution and Commercialization of XOLREMDI® (mavorixafor) in WHIM Syndrome in Select Middle East Countries

   GlobeNewswire FEB 19, 2025 7:35 AM EST
   BOSTON and DUBAI, United Arab Emirates, Feb. 19, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals ...
   READ ARTICLE

8. X4 Pharmaceuticals Announces Strategic Restructuring to Drive Value and Maximize Opportunity for Mavorixafor in Chronic Neutropenia

   GlobeNewswire FEB 6, 2025 7:35 AM EST
   Full enrollment in ongoing global, pivotal Phase 3 clinical trial in chronic neutropenia on...
   READ ARTICLE

9. X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire FEB 3, 2025 4:05 PM EST
   BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company dr...
   READ ARTICLE

10. X4 Pharmaceuticals Announces EMA Validation of Marketing Authorization Application (MAA) for Mavorixafor for the Treatment of WHIM Syndrome

    GlobeNewswire JAN 24, 2025 7:36 AM EST
    Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. ...
    READ ARTICLE